Mergers & Acquisitions ·
Galmed Pharmaceuticals Ltd. rebranded as Eocene Ltd., changing its Nasdaq ticker symbol from GLMD to EOCN effective…
GLMDGalmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. rebranded as Eocene Ltd., changing its Nasdaq ticker symbol from GLMD to EOCN effective September 10, 2026, to reflect a strategic pivot toward gastrointestinal innovation following the acquisition of Colospan Ltd. The company also terminated its Standby Equity Purchase Agreement with Yorkville, having raised approximately $7.3 million through the issuance of 437,947 ordinary shares prior to termination. Shareholders approved amendments to the Articles of Association at an Annual General Meeting on September 3, 2026. Eocene Ltd. is a gastrointestinal-focused medtech and biopharmaceutical company developing therapeutic and device solutions for GI diseases and cancers.